Summary of the Conference Call for 开拓药业 (Kaituo Pharmaceutical) Company Overview - **Company**: Kaituo Pharmaceutical - **Industry**: Pharmaceutical and Cosmetics Key Points Strategic Transformation - The company is undergoing a strategic transformation towards dermatology, aiming for gross profit to turn positive by 2025 and achieving both cash flow and profitability by 2027 [2][4] - The decision for transformation was influenced by excessive investment in COVID-19 projects, which impacted financial stability and focus [4] Financial Performance and Projections - Projected revenue for 2025 is expected to increase from 5 million RMB in 2024 to 32.7 million RMB, a growth of approximately 550% [3] - Domestic cosmetics sales are projected at 24.3 million RMB, with overseas sales at 5.9 million RMB, both showing a 500% increase [3] - The company anticipates a significant increase in sales for its core products, KX-826 and GT20,029, with KX-826 expected to generate 120 million RMB in 2026 [5][12] Product Development and Clinical Trials - KX-826 has successfully completed Phase III clinical trials, showing better safety compared to Minoxidil, with a pricing strategy set to be 50%-100% higher than competitors [2][7] - GT20,029 is positioned as a third-generation tyrosinase inhibitor, targeting a market previously dominated by older products [5][10] Marketing Efficiency - Marketing efficiency for the ToC (Consumer) segment has improved significantly, with the input-output ratio moving from 4.4:1 in 2024 to approximately 1:1 by early 2026 [2][3] Business Development and Partnerships - The company is actively pursuing business development (BD) opportunities, including licensing non-dermatology pipelines and overseas rights to alleviate financial pressure [2][5] - Plans to collaborate with major cosmetic brands for GT19,939 to enhance market penetration and brand recognition [12][14] Challenges and Responses - The company is addressing patent challenges raised by Bayer, asserting that scientific data supports their position and enhances product awareness [2][9] - Despite challenges, the company views increased scrutiny as an opportunity to elevate the profile of GT19,939 in the market [12][13] Future Outlook - The company aims to transition from a research-focused entity to a commercialized company while maintaining a strong emphasis on R&D [4][5] - Expected sales for GT19,939 in 2026 are projected to reach 2-3 tons, with significant growth anticipated in 2027 [12][13] Market Positioning - KX-826 is targeted at the mass market, while GT20,029 is aimed at the high-end market, potentially combining with professional channels for greater value [10][11] - The company is exploring combination therapies to enhance treatment efficacy and patient adherence [10][11] Conclusion - Kaituo Pharmaceutical is strategically positioning itself within the dermatology sector, with ambitious growth targets and a focus on innovative product development. The company is navigating challenges while leveraging opportunities for market expansion and brand recognition.

SinoMab BioScience Limited 中 國 抗 體 製 藥 有 限 公 司 （於香港註冊成立的有限公司） （股份代號：3681） 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 茲提述中國抗體製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）所刊發 日 期 為 二 零 二 二 年 二 月 十 六 日 、 二 零 二 二 年 三 月 十 四 日 、 二 零 二 二 年 六 月 十 五 日 、 二 零 二 三 年 五 月 二 十 二 日 、 二 零 二 三 年 六 月 十 二 日 、 二 零 二 三 年 八 月 十 四 日、二零二三年九月十一日、二零二三年十一月二十七日、二零二四年六月十一 日、二零二五年四月七日、二零二五年十月十四日、二零二五年十二月十一日、 二零二六年二月二十四日及二零二六年三月二十五日的公告，內容有關本集團主 要產品之一SM17研發進展的最新資料 ...

Core Viewpoint - Rongchang Biopharmaceutical (688331.SH) has received approval from the National Medical Products Administration for the clinical trial of its dual-target ADC drug RC288, aimed at treating locally advanced unresectable or metastatic malignant solid tumors in Phase I/IIa trials [1] Group 1: Drug Development - RC288 is a dual-specific ADC that targets both PSMA and B7H3, developed using next-generation conjugation and toxin technology [1] - PSMA (Prostate-Specific Membrane Antigen) is a type II transmembrane glycoprotein that supports tumor growth and angiogenesis [1] - B7H3 is an immune checkpoint molecule that, when overexpressed in tumors, promotes immune evasion and tumor progression [1] Group 2: Market Potential - Both PSMA and B7H3 are highly promising therapeutic targets, expressed in various malignant tumor tissues and newly formed tumor blood vessels, and are involved in tumor proliferation, invasion, and drug resistance signaling pathways [1]

Core Viewpoint - Rongchang Biopharmaceutical (688331.SH) has received approval from the National Medical Products Administration for its clinical trial of the dual-antibody ADC drug RC288, aimed at treating locally advanced unresectable or metastatic malignant solid tumors in I/IIa phases [1]. Group 1 - The company announced the receipt of the clinical trial approval notice on April 1 [1]. - The drug RC288 is a self-developed dual-antibody ADC targeting specific cancer types [1]. - The approval marks a significant step in the company's research and development efforts in oncology [1].

Core Viewpoint - Rongchang Biopharma has received approval from the National Medical Products Administration for its self-developed dual-target ADC drug RC288, which is intended for the treatment of locally advanced unresectable or metastatic malignant solid tumors in a Phase I/IIa clinical trial [1] Group 1: Drug Development - RC288 is a bispecific ADC that targets both PSMA and B7H3, developed using next-generation conjugation and toxin technology [1] - PSMA and B7H3 are highly promising therapeutic targets, expressed in various malignant tumor tissues and tumor neovascularization, and are involved in tumor proliferation, invasion, and drug resistance signaling pathways [1]

Investment Rating - The report maintains an "Outperform" rating for Innovent Biologics [2] Core Insights - Innovent Biologics achieved total revenue of RMB 13.0 billion in FY25, representing a year-on-year growth of 38%, with product sales revenue reaching RMB 11.9 billion, up 45% [3][15] - The company turned a net profit attributable to shareholders of RMB 810 million in FY25, compared to a loss of approximately RMB 100 million in the previous year [3][15] - The gross margin improved to 86.5%, an increase of 2.6 percentage points year-on-year [3][15] - The company expects to recognize out-licensing revenue progressively starting in 2026, with significant upfront payments from collaborations with Roche and Takeda [5][17] - The core asset IBI363 (PD-1/IL-2) is advancing smoothly, with three assets entering global Phase III clinical trials, estimated to have a combined addressable market exceeding USD 60 billion [19][21] Financial Summary - Revenue projections for FY26 and FY27 have been raised to RMB 17.8 billion and RMB 20.5 billion, respectively, along with net profit forecasts of RMB 2.3 billion and RMB 3.5 billion [10][21] - The company’s selling expenses increased by 31% year-on-year to RMB 5.7 billion, while R&D expenses decreased by 2% to RMB 2.6 billion [3][15] - The report indicates a strong organic sales growth driven by the oncology franchise and the expansion of the product portfolio, with multiple products included in the National Reimbursement Drug List (NRDL) expected to drive further growth in 2026 [4][16]

Group 1 - The company Sinopharm (01801) announced the granting of stock options and restricted shares to a total of 1,374 participants, including directors, under the 2024 share plan [2] - Specifically, 1.9356 million stock options were granted to 66 participants, while 10.2413 million restricted shares were granted to 1,308 participants, pending acceptance by the grantees [2]

Investment Rating - The report maintains an "Outperform" rating for Innovent Biologics [2] Core Insights - Innovent Biologics achieved total revenue of RMB 13.0 billion in FY25, representing a year-on-year growth of 38%, with product sales revenue reaching RMB 11.9 billion, up 45% [3][15] - The company turned a net profit attributable to shareholders of RMB 810 million in FY25, compared to a loss of approximately RMB 100 million in the previous year [3][15] - The gross margin improved to 86.5%, an increase of 2.6 percentage points year-on-year [3][15] - The report highlights strong organic sales growth driven by the oncology franchise and the expansion of the product portfolio, with multiple products included in the National Reimbursement Drug List (NRDL) expected to further boost sales in 2026 [4][16] - Out-licensing revenue of RMB 957 million was recognized in FY25, with significant upfront payments from collaborations with Roche and Takeda expected to be progressively recognized in the financial statements from 2026 onward [5][17] - The core asset IBI363 (PD-1/IL-2) is advancing smoothly, with three assets entering global Phase III clinical trials, estimated to have a combined addressable market exceeding USD 60 billion [7][19] - The early-stage pipeline shows strong global competitiveness, with 11 new molecules advanced into clinical development, expected to yield early data in 2026-2027 [9][20] - The target price is adjusted to HKD 107.40 based on a DCF model, reflecting an increase in revenue and net profit forecasts for 2026 and 2027 [10][21]

Group 1 - A small biopharmaceutical firm received a significant boost after Biogen agreed to acquire it for $5.6 billion [1]

Robotics - The core advancement in Xiaomi's robotic dexterous hand includes a tactile coverage area of 8200 square millimeters, enhancing full palm perception and efficient data collection [2][8] - The demand for high-performance actuators is expected to surge due to the public unveiling of the "machine wolf" combat training footage, indicating a shift towards more complex operational scenarios [9] - The humanoid robotics industry is anticipated to transition from small-scale validation to a new phase of growth, with significant attention on upstream components and main manufacturers [9][10] Consumer Electronics - Xtep International reported a revenue of 14.15 billion yuan for 2025, reflecting a year-on-year increase of 4.2%, with a net profit of 1.37 billion yuan, up 10.8% [13][14] - The company maintains a strong dividend policy with a payout ratio exceeding 50%, indicating robust shareholder returns [14][15] - The professional sports segment, including brands like Saucony and Maile, saw a revenue increase of 30.8%, highlighting a successful high-end positioning strategy [15][16] Food and Beverage - Weilian Meiwai achieved a revenue of 7.224 billion yuan in 2025, marking a 15.3% year-on-year growth, with a net profit increase of 33.4% [18][19] - The company’s vegetable products segment, particularly the konjac category, has driven significant growth, with a notable increase in offline distribution efficiency [19][20] - The company is exploring overseas markets, with international revenue growing by 48% in 2025, indicating potential for further expansion [19][20] New Consumption - Ruoyuchen reported a total revenue of 3.432 billion yuan in 2025, a remarkable growth of 94.35%, with self-owned brands contributing significantly to this increase [21][22] - The self-owned brand segment achieved a revenue of 1.813 billion yuan, up 261.94%, underscoring its role as a key growth driver [22][23] - The brand management and e-commerce operations have shown strong development, with revenue contributions of 895 million yuan and 723 million yuan, respectively [23][24] Utilities and Environmental Protection - China Coal Energy reported a revenue of 148.06 billion yuan for 2025, a decrease of 21.8%, with a net profit of 17.88 billion yuan, down 7.3% [26][27] - The company has focused on cost reduction strategies to mitigate the impact of declining coal prices, achieving a unit sales cost of 252 yuan per ton, down 10.7% year-on-year [27][28] - The company anticipates a rebound in coal prices and chemical product prices in 2026, which could enhance profitability [28][30] Transportation - COSCO Shipping Special reported a revenue of 23.211 billion yuan for 2025, reflecting a growth of 38.32%, with a net profit of 1.78 billion yuan, up 16.29% [33][34] - The multi-purpose vessel segment remains a stable revenue source, contributing approximately 57.17% of total revenue, with new vessel acquisitions expected to drive further growth [34][35] - The company plans to expand its fleet significantly, with expectations to increase its total cargo volume to over 31 million tons by 2026 [35][36] Pharmaceuticals - WuXi XDC, a leading CRDMO in the bioconjugate drug sector, reported a revenue of 5.944 billion yuan for 2025, a 46.7% increase, with a net profit margin improvement [38] - The company has seen a significant rise in its order backlog, with a total of 252 projects, indicating strong future growth potential [38]